TORONTO--(BUSINESS WIRE)--Novel Biotechnology Inc., an innovative biotechnology start-up headquartered in Canada, is pleased to announce the successful completion of its $2.5 million seed round funding. This significant milestone was achieved with the support of angel investors, along with the Ontario Center of Innovation (OCI), which provided $500,000..

多伦多-（商业线）-总部设在加拿大的创新生物技术初创公司Novel Biotechnology Inc.很高兴宣布成功完成250万美元的种子轮资助。这一重要里程碑是在天使投资者的支持下实现的，安大略省创新中心（OCI）提供了50万美元。。

Novel Biotechnology is dedicated to pioneering a groundbreaking platform technology for the production of plasmid DNA, a critical reagent in the modern biopharmaceutical industry. Their platform promises to deliver enhanced productivity, speed, and quality, setting a new standard in the field.

新型生物技术致力于开创开创性的平台技术，用于生产质粒DNA，这是现代生物制药行业的关键试剂。他们的平台承诺提高生产力，速度和质量，为该领域树立新标准。

Co-founded by CEO Pankaj Khanna and a team of accomplished serial entrepreneurs, Novel Biotechnology is on a mission to revolutionize the plasmid DNA market. In recent years, the industry has grappled with capacity constraints, hindering progress in vaccine and gene therapy research and development..

新型生物技术由首席执行官Pankaj Khanna和一个有成就的连续企业家团队共同创立，其使命是彻底改变质粒DNA市场。近年来，该行业应对能力限制，阻碍了疫苗和基因治疗研究与开发的进展。。

'A dramatic increase in the amount of R&D taking place in the vaccine and gene therapy sectors has created a shortage in global pDNA manufacturing capacity. Additionally, the pDNA products that researchers need continue to get larger and more complex, pushing the limits of existing manufacturing technologies,” said Matthew Weinstock, CTO of Novel Biotechnology.

“疫苗和基因治疗领域研发数量的急剧增加导致全球pDNA制造能力短缺。此外，研究人员需要的pDNA产品继续变得越来越大，越来越复杂，推动了现有制造技术的局限性，“新型生物技术首席技术官Matthew Weinstock说。

“Our NBx platform is an engineered microbial strain that is significantly more productive, can handle complex constructs, offers improved product quality profiles, and can be slotted into existing manufacturing infrastructure without requiring any modifications.'.

“我们的NBx平台是一种工程微生物菌株，其产量显着提高，可以处理复杂的结构，提供改进的产品质量概况，并且可以投入现有的制造基础设施而无需任何修改。”。

One of the key advantages of Novel's NBx technology is its high productivity, which enables a smaller footprint, making it mobile and easy to deploy.

新型NBx技术的关键优势之一是其高生产率，占地面积更小，使其移动且易于部署。

'The recent pandemic experience has taught us that the world needs compact and mobile manufacturing systems that can be readily deployed across the globe to improve access to life-saving medicines,' said CEO Pankaj Khanna.

首席执行官Pankaj Khanna说：“最近的大流行经验告诉我们，世界需要紧凑和移动的制造系统，可以在全球范围内轻松部署，以改善获得救生药物的机会。

Since its inception, Novel has achieved significant milestones, including the development of its proprietary strain, proof of concept with multiple plasmid constructs, and the generation of meaningful revenue through its services business. The proceeds from the seed round will be utilized to expand Novel's existing plasmid services business and expedite its platform R&D initiatives..

自成立以来，小说取得了重大里程碑，包括开发其专有菌株，使用多种质粒构建体进行概念验证，以及通过其服务业务产生有意义的收入。种子轮的收益将用于扩展Novel现有的质粒服务业务并加快其平台研发计划。。

“Through the Ontario Centre of Innovation, our government is proud to support innovative start-ups like Novel Biotechnology,” said Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. “Their breakthroughs in vaccine and gene therapy research will build on Ontario’s long history of innovation in the life sciences sector.

安大略省经济发展，创造就业和贸易部长维奇·费德利（Vic Fedeli）说：“通过安大略省创新中心，我们的政府很自豪地支持像新型生物技术这样的创新初创企业。”。“他们在疫苗和基因治疗研究方面的突破将建立在安大略省生命科学领域长期的创新历史之上。

Congratulations, Novel Biotechnology.”.

祝贺，新型生物技术。”。

'Due to the strong growth within the pDNA market, Novel expects robust revenue growth and profitability by FY2025,' said Konstantin Rodionov, CFO & Co-Founder of Novel Biotechnology.

“由于pDNA市场的强劲增长，Novel预计到2025年将有强劲的收入增长和盈利能力，”CFO和新型生物技术联合创始人Konstantin Rodionov说。

Over the past several months, Novel has been diligently conducting tests on complex plasmid constructs and scaling up its proprietary platform in collaboration with external partners. The company is excited to announce the commercial launch of NBx for plasmid manufacturing in Q4, 2023.

在过去的几个月中，Novel一直在努力对复杂的质粒构建体进行测试，并与外部合作伙伴合作扩大其专有平台。该公司很高兴在2023年第四季度宣布NBx商业推出质粒制造。

In the interim, Novel will continue to leverage established platforms to produce R&D and pre-clinical plasmid material for its existing industrial and academic clients.

在此期间，小说将继续利用已建立的平台为其现有的工业和学术客户生产研发和临床前质粒材料。

“Considering the lessons learned from the recent pandemic, compact and mobile manufacturing systems are essential for ensuring broader access to life-saving medicines. Novel Biotechnology is well-positioned to lead the charge in addressing critical capacity constraints in the plasmid DNA market and contributing to advancements in the biopharmaceutical industry,” said President and CEO of the Ontario Centre of Innovation, Claudia Krywiak..

“考虑到最近大流行的经验教训，紧凑和移动的制造系统对于确保更广泛地获得挽救生命的药物至关重要。新型生物技术已经很好地领导着解决质粒DNA市场的关键能力限制并为进步做出贡献生物制药行业的总裁兼首席执行官说安大略省创新中心，Claudia Krywiak。。

About Novel Biotechnology Inc.:

关于新型生物技术公司：

Novel Biotechnology Inc. is a pioneering biotechnology start-up headquartered in Canada. Founded by CEO Pankaj Khanna and a team of seasoned entrepreneurs, the company is committed to developing innovative solutions for plasmid DNA production, catering to the growing demands of the biopharmaceutical industry.

Novel Biotechnology Inc.是总部设在加拿大的开拓性生物技术初创企业。该公司由首席执行官Pankaj Khanna和经验丰富的企业家团队创立，致力于开发质粒DNA生产的创新解决方案，以满足生物制药行业日益增长的需求。

Novel Biotechnology's NBx platform promises to deliver superior productivity, speed, and quality, setting new standards in the field. For more information, visit www.novelbiologics.com..

新型生物技术的NBx平台承诺提供卓越的生产力，速度和质量，为该领域设定新的标准。欲了解更多信息，请访问www.novelbiologics.com。。

About the Ontario Centre of Innovation:

关于安大略省创新中心：

The Ontario Centre of Innovation (OCI) brings industry, academic, and government partners together to invest in collaborative R&D, technology development, and commercialization opportunities that generate the highest return on innovation for Ontarians.

安大略省创新中心（OCI）将行业，学术界和政府合作伙伴聚集在一起，投资合作研发，技术开发和商业化机会，为安大略省居民带来最高的创新回报。

As an ecosystem connector, OCI initiates unparalleled partnership opportunities, develops and manages successful industry-academic collaborations, supports high-potential SMEs in commercializing ground-breaking research, and provides hands-on training and skills development opportunities for the next generation of highly skilled talent..

作为一个生态系统连接器，OCI启动无与伦比的合作机会，开发和管理成功的行业学术合作，支持高潜力中小企业商业化突破性研究，并为下一代高技能人才提供实践培训和技能发展机会。。

OCI drives economic growth and job creation through investments in the development, commercialization, and adoption of advanced technologies. For more information: https://www.oc-innovation.ca

OCI通过投资开发，商业化和采用先进技术来推动经济增长和创造就业机会。欲了解更多信息：https://www.oc-innovation.ca